FANCL germline (heterozygous) in EOC: Fanconi-anemia-pathway gene; biallelic loss = Fanco...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-FANCL-GERMLINE-OVARIAN |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-OVARIAN |
| Sources | SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | FANCL germline pathogenic (heterozygous) |
| Disease | DIS-OVARIAN |
| ESCAT tier | IIIA |
| Recommended combinations | niraparib (HRD-positive), olaparib + bevacizumab |
| Evidence summary | FANCL germline (heterozygous) in EOC: Fanconi-anemia-pathway gene; biallelic loss = Fanconi anemia (recessive). Heterozygous carriers have uncertain cancer risk. FANCL included in some HRR panels (FANCL on PROfound HRR list). PARPi off-label consideration in HRD-positive. ESCAT IIIA / OncoKB Level 3B. |
Notes
Heterozygous FANCL actionability uncertain; biallelic loss = Fanconi anemia (avoid radiation, alkylators if applicable). Cascade testing case-by-case.
Used By
No reverse references found in the YAML corpus.